ออฟไลน์ด้วยแอป Player FM !
Mark Erlander of Cardiff Oncology, Inc. Discusses KRAS Mutations in Cancer | Podcast S2 E39
Manage episode 297076267 series 2949236
Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here
82 ตอน
Manage episode 297076267 series 2949236
Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here
82 ตอน
Alla avsnitt
×ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ